Introduction of medical products into healthcare practice and costs reimbursement: European experience
in the present article, we review the ways of introducing medical products into healthcare practice in countries of the european Union and compare them with the Russian experience. in this analysis, we underscore the existing differences but also identify the common aspects, for example, the mandato...
Saved in:
| Main Authors: | V. V. Omelyanovsky, S. S. Otstavnov, N. Z. Musina, V. S. Dombrovskii |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2018-08-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/252 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
by: Bérengère Macabeo, et al.
Published: (2023-12-01) -
Health technology assessment and reimbursement of pharmaceuticals in Italy
by: F. V. Gorkavenko, et al.
Published: (2019-07-01) -
APPROACHES TO REIMBURSEMENT FOR MEDICAL CARE WITHIN ANESTHESIOLOGY AND INTENSIVE CARE PROFILE DURING TRANSFER TO A NEW SYSTEM OF HEALTH CARE FUNDING
by: Yu. S. Polushin, et al.
Published: (2018-01-01) -
Analysing criteria for price and reimbursement of orphan drugs in Spain
by: Xavier Badia, et al.
Published: (2019-07-01) -
Delayed access to innovative medicines in Romania: a comprehensive analysis of the reimbursement processes (2015–2024)
by: Constantin Radu, et al.
Published: (2025-05-01)